Sun Pharma net profit falls on US antitrust settlement, drug disability cost | Today news

Sun Pharmaceutical Industries Ltd’s revenue from operations for the April-June period beat the expectations of the street to 9.4% year-on-year to £ 13.851. However, the drug maker’s net profit fell on extraordinary items, including settlement costs in a price of antitrust litigation in the US and the cessation of clinical studies on one of his medicine. The company achieved a net profit of £ 2.279 crore in Q1FY26, 20% lower than a year earlier. A healthy double-digit growth in the Indian Business and Innovative Medicines Pipeline increased its turnover and ebitda margins during the term. The drug manufacturer both segments banked to drive the growth in FY26. The adjusted net profit, excluding the exceptional items, for Q1FY26 was £ 2.996 crore, up 5.7%, Sun Pharma said in a scholarship on Thursday. “Sun had a strong performance during the quarter, where total growth reflects steady progress on all our markets. India still shows a strong momentum, and contributes significantly to our performance,” Dilip Shanghvi, chairman and managing director, said in the statement. Sun Pharma and its subsidiary Taro Pharmaceuticals have agreed to pay $ 200 million to settle a generic antitrust prize litigation in the US earlier this month. The company also announced that it was stopping studies on the drug candidate SCD-044 for atopic dermatitis, after the drug did not achieve the primary goals in Phase-2 trials. A 14 -brokerage survey of 14 brokers estimated that the revenue of the firm is £ 13,699 crore, and the profit after tax at £ 3.042 crore. Sun Pharma reported an EBITDA (earnings before interest, tax, depreciation and amortization) of £ 4,302 crore, with 19.2%, with the margin expanding to 31.1%. The increase in Ebitda margin was due to improvement in raw material costs, as well as higher sales of its global specialty products and formulations for domestic brands, the company’s chief financial officer, Jayashree Satagopan, told investors on Thursday night. The share price of Sun Pharma fell 2% lower at £ 1,700 on the NSE on Thursday. Robust India, the domestic company of Speciality Growth Sun Pharma had a strong double -digit growth, which maintains its momentum. India sales rose 13.9% years old to £ 4.721 crore. The growth has been powered by an increase in volume as well as new product launches, as opposed to the overall Indian pharmaceutical market that largely grows on the back of the price increases. The company has seen an increase in its global sales of specialty or innovative medicines, rising 16.9% to $ 311 million. This segment was 19.3% of its quarterly sales and increased total US sales. The company reported a total US sales of $ 473 million, with 1.4%. “This growth is powered by our innovative medicine portfolio, with all our growth products contributing, including Ilumya, Cequa, Winlevi and Odomzo, but counteracted by the decline in our generics business due to additional competition in certain products,” Richard Ascroft, North American executive, which will lose the company, to lose excel. The US accounted for 29.3% of consolidated sales sales. Sun Pharma has launched its medicine for severe Alopecia Areata, LeQselvi, in the US in the US. “We are greatly encouraged by early results, we have seen good receptivity with healthcare staff and patients, and we already have our initial commercial prescriptions,” Asproft said. Sun Pharma is ready for the launch of Cancer Drug Undcyt in the second half of FY26, the company said.